Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
You may also be interested in...
The French drug firm Sanofi is bullish on producing some of its products in India. It first acquired Shantha Biotechnics and it manufacturing capabilities in 2009 and later started making its pen devices locally, and is now setting up a large project to make the human insulin product Insuman.